Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

Type

Industry

Walgreens Boots Alliance

Announced: March 7, 2025
Value: $26.1 billion
Status: Pending

Exclusive financial advisor to Walgreens Boots Alliance on the take-private transaction of WBA by Sycamore Partners

Emerson Electric Co.

Announced: January 27, 2025
Value: $16.8 billion
Status: Pending

Financial advisor to Emerson on its acquisition of AspenTech

Intra-Cellular Therapies

Announced: January 13, 2025
Value: $14.6 billion
Status: Pending

Centerview acted as lead financial advisor to Intra-Cellular on its sale to Johnson & Johnson

Scorpion Therapeutics

Announced: January 13, 2025
Value: Up to $2.5 billion
Status: Pending

Centerview acted as lead financial advisor to Scorpion on its sale to Eli Lilly

PepsiCo, Inc.

Announced: March 17, 2025
Value: $1.95 billion
Status: Pending

Lead financial advisor to PepsiCo on its acquisition of poppi

Alani Nutrition LLC

Announced: February 20, 2025
Value: $1.8 billion
Status: Pending

Financial advisor to certain Alani Nu shareholders

Evident Corporation

Announced: January 14, 2025
Value: $1.78 billion
Status: Pending

Centerview served as lead financial advisor to Bain Capital and Evident in their sale of Evident's Inspection Technologies division to Wabtec

IDRx

Announced: January 13, 2025
Value: Up to $1.15 billion
Status: Pending

Exclusive advisor to IDRx on its sale to GSK

Araris Biotech

Announced: March 17, 2025
Value: Up to $1.1 billion
Status: Pending

Exclusive financial advisor to Araris on its acquisition by Taiho Pharmaceutical, a subsidiary of Otsuka Holdings

EsoBiotec

Announced: March 17, 2025
Value: Up to $1.0 billion
Status: Pending

Exclusive financial advisor to EsoBiotec on its acquisition by AstraZeneca

Evergreen Theragnostics, Inc.

Announced: January 28, 2025
Value: Up to $1.0 billion
Status: Pending

Exclusive financial advisor to Evergreen on its sale to Lantheus

Bolt Medical

Announced: January 8, 2025
Value: Up to $900 million
Status: Pending

Exclusive advisor to Bolt on its sale to Boston Scientific

Simple Mills

Announced: January 8, 2025
Value: $795 million
Status: Pending

Served as financial advisor to Simple Mills on its sale to Flowers Foods

ChampionX

Announced: February 25, 2025
Value: $300 million
Status: Pending

Exclusive financial advisor to ChampionX in its divestiture of US Synthetic to LongRange Capital

Henry Schein Inc.

Announced: January 29, 2025
Value: $250 million
Status: Pending

Exclusive financial advisor to Henry Schein in its strategic investment by KKR and board change

Zealand Pharma

Announced: March 12, 2025
Status: Closed

Financial advisor to Zealand Pharma on its global collaboration and license agreement with Roche

Chimerix

Announced: March 5, 2025
Value: $935mm
Status: Pending

Exclusive financial advisor to Chimerix on its sale to Jazz Pharmaceuticals

Cutera, Inc.

Announced: March 5, 2025
Status: Pending

Exclusive investment banker and financial advisor to the Ad Hoc Group of Cutera's convertible note holders in its filing for chapter 11 and subsequent comprehensive restructuring transaction

Repligen Corporation

Announced: March 4, 2025
Status: Pending

Sole financial advisor to Repligen on its acquisition of 908 Devices' Bioprocessing PAT portfolio

Apax Partners LLP

Announced: February 28, 2025
Status: Pending

Financial advisor to Apax on its strategic investment in ECI Software Solutions

Teleflex, Inc.

Announced: February 27, 2025
Status: Pending

Sole financial advisor to Teleflex on its separation transaction and strategic advisor to the company on its value creation framework

Honeywell International Inc.

Announced: February 6, 2025
Status: Pending

Financial advisor to Honeywell on the separation of its Automation and Aerospace businesses into two separate public companies

Aptiv PLC

Announced: January 22, 2025
Status: Pending

Financial advisor to Aptiv on its plan to spin-off its Electrical Distribution Systems business

JOANN Inc.

Announced: January 15, 2025
Status: Pending

Exclusive investment banker to JOANN in its filing for chapter 11 bankruptcy

Alacrity Solutions Group

Announced: January 8, 2025
Status: Pending

Exclusive financial advisor to Alacrity on its strategic transaction for long-term growth

Advent International

Announced: January 6, 2025
Status: Pending

Financial advisor to Advent International on its acquisition of Sauer Brands

The Walt Disney Company

Announced: January 6, 2025
Status: Pending

Exclusive financial advisor to The Walt Disney Company in its combination of Hulu and its live TV business with Fubo

Showing 1 to 27 of 27
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.
Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.
New York

Centerview Partners LLC


31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax
London

Centerview Partners UK LLP


1 Sherwood Street

6th Floor

London W1F 7BL

02074099700 | Tel
02074099704 | Fax
Paris

Centerview Partners France SCS


51 Avenue Hoche


Paris 75008

0180200620 | Tel
0180200621 | Fax
Menlo Park

Centerview Partners LLC


1302 El Camino Real

Suite 350

Menlo Park, California 94025

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC


555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax





Copyright © 2008 - 2025 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC